July 31, 2014 by Arezu Sarvestani
Medical device startups face significant headwinds in finding funding and getting to an exit, but at least prospective buyers are a little more willing to gamble on companies that haven’t yet made it through the FDA.
Report: Medtech M&A no longer hinges on FDA approval
The funding environment for medical device startups isn’t a pretty scene, but there is a ray of sunshine through the gloom: lack of FDA approval is no longer a deal-breaker for a big exit.
In 2013 a few medtech companies managed “big exit M&A” deals (those worth $50 million or more) without having reached the FDA’s brass ring, according to a new report from Silicon Valley Bank.
